Advice
following a full submission:
doxylamine succinate and pyridoxine hydrochloride (Xonvea®) is not recommended for use within NHSScotland.
Indication under review: the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.
Doxylamine in combination with pyridoxine significantly improved symptoms of nausea and vomiting compared with placebo in women with nausea and vomiting of pregnancy.
The submitting company did not present a sufficiently robust clinical or economic analysis to gain acceptance by SMC.
The license holder has indicated their intention to resubmit.
Medicine details
- Medicine name:
- doxylamine succinate and pyridoxine hydrochloride (Xonvea)
- SMC ID:
- SMC2140
- Indication:
- for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management
- Pharmaceutical company
- Alliance Pharma
- BNF chapter
- Gastro-intestinal system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 13 May 2019